CN103436492A - 通过无血清培养扩增活化淋巴细胞的方法 - Google Patents
通过无血清培养扩增活化淋巴细胞的方法 Download PDFInfo
- Publication number
- CN103436492A CN103436492A CN2013103346666A CN201310334666A CN103436492A CN 103436492 A CN103436492 A CN 103436492A CN 2013103346666 A CN2013103346666 A CN 2013103346666A CN 201310334666 A CN201310334666 A CN 201310334666A CN 103436492 A CN103436492 A CN 103436492A
- Authority
- CN
- China
- Prior art keywords
- cell
- culture
- serum
- lymphocyte
- free medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004698 lymphocyte Anatomy 0.000 title claims abstract description 94
- 238000000034 method Methods 0.000 title claims abstract description 80
- 230000003213 activating effect Effects 0.000 title abstract description 3
- 230000002062 proliferating effect Effects 0.000 title abstract 2
- 239000012679 serum free medium Substances 0.000 claims abstract description 43
- 230000004913 activation Effects 0.000 claims abstract description 21
- 239000012472 biological sample Substances 0.000 claims abstract description 8
- 230000003321 amplification Effects 0.000 claims description 56
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 56
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 108090000695 Cytokines Proteins 0.000 claims description 12
- 102000004127 Cytokines Human genes 0.000 claims description 12
- 108010002350 Interleukin-2 Proteins 0.000 claims description 8
- 108010002586 Interleukin-7 Proteins 0.000 claims description 7
- 230000000527 lymphocytic effect Effects 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 4
- 238000012258 culturing Methods 0.000 abstract description 16
- 238000009169 immunotherapy Methods 0.000 abstract description 12
- 230000035755 proliferation Effects 0.000 abstract 4
- 239000012190 activator Substances 0.000 abstract 1
- 238000003306 harvesting Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 74
- 206010028980 Neoplasm Diseases 0.000 description 17
- 238000004113 cell culture Methods 0.000 description 14
- 239000006143 cell culture medium Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 11
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 10
- 210000005259 peripheral blood Anatomy 0.000 description 10
- 239000011886 peripheral blood Substances 0.000 description 10
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 230000001413 cellular effect Effects 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000002504 physiological saline solution Substances 0.000 description 8
- 239000000523 sample Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 239000006285 cell suspension Substances 0.000 description 5
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- YWGKLJXXVGSTCN-UHFFFAOYSA-N [Na].P(O)(O)(O)=O.[Cl] Chemical compound [Na].P(O)(O)(O)=O.[Cl] YWGKLJXXVGSTCN-UHFFFAOYSA-N 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000013016 damping Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000009849 Female Genital Neoplasms Diseases 0.000 description 1
- 206010016825 Flushing Diseases 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010048612 Hydrothorax Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 239000000877 Sex Attractant Substances 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 208000006593 Urologic Neoplasms Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 201000004637 gastric cardia carcinoma Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
性别 | 男 |
男 | 75 |
女 | 68 |
合计 | 143 |
年龄 | 人数 |
2~10 | 16 |
11~20 | 11 |
21~40 | 11 |
41~60 | 55 |
61~82 | 50 |
合计 | 143 |
肿瘤类型 | 人数 |
血液肿瘤 | 35 |
消化道肿瘤 | 39 |
肉瘤 | 3 |
肝胆肿瘤 | 21 |
呼吸系统肿瘤 | 22 |
妇科肿瘤 | 12 |
乳腺癌 | 4 |
泌尿系统肿瘤 | 2 |
其他 | 5 |
合计 | 143 |
Claims (12)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310334666.6A CN103436492B (zh) | 2013-08-02 | 2013-08-02 | 通过无血清培养扩增活化淋巴细胞的方法 |
HK14105496.2A HK1192282A1 (zh) | 2013-08-02 | 2014-06-11 | 通過無血清培養擴增活化淋巴細胞的方法 |
PCT/CN2014/083368 WO2015014291A1 (zh) | 2013-08-02 | 2014-07-31 | 通过无血清培养扩增活化淋巴细胞的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310334666.6A CN103436492B (zh) | 2013-08-02 | 2013-08-02 | 通过无血清培养扩增活化淋巴细胞的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103436492A true CN103436492A (zh) | 2013-12-11 |
CN103436492B CN103436492B (zh) | 2016-03-02 |
Family
ID=49690210
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310334666.6A Active CN103436492B (zh) | 2013-08-02 | 2013-08-02 | 通过无血清培养扩增活化淋巴细胞的方法 |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN103436492B (zh) |
HK (1) | HK1192282A1 (zh) |
WO (1) | WO2015014291A1 (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107208061A (zh) * | 2014-12-05 | 2017-09-26 | 伦敦国王学院 | γδ T细胞扩增方法 |
CN112662625A (zh) * | 2021-01-18 | 2021-04-16 | 杭州原生生物科技有限公司 | 一种t细胞培养基及其用于t细胞的扩增培养方法 |
CN114984048A (zh) * | 2022-06-16 | 2022-09-02 | 浙江百越生物技术有限公司 | 一种预防与治疗老年人行动迟缓的细胞疗法 |
CN116355846A (zh) * | 2021-12-28 | 2023-06-30 | 北京永泰生物制品有限公司 | 一种质量稳定可控的扩增活化淋巴细胞的方法及其用于防治神经科疾病中的用途 |
CN116355845A (zh) * | 2021-12-28 | 2023-06-30 | 北京永泰生物制品有限公司 | 一种质量稳定可控的扩增活化淋巴细胞的方法及其用于抗肿瘤用途 |
CN117965445A (zh) * | 2024-04-02 | 2024-05-03 | 上海药明巨诺生物医药研发有限公司 | 一种用于细胞培养的组合物 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112251407A (zh) * | 2020-11-03 | 2021-01-22 | 广州康琪莱精准医疗科技有限公司 | 一种脐带血cik细胞的扩增培养方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1990044A (zh) * | 2005-12-30 | 2007-07-04 | 上海中科英达生物技术有限公司 | 人体免疫活性细胞dccik抗肿瘤细胞制剂的制备方法及应用 |
CN101063108A (zh) * | 2007-04-25 | 2007-10-31 | 哈尔滨医科大学 | 一种高增殖力、高细胞毒活性cik细胞的制备方法 |
WO2011103882A1 (en) * | 2010-02-24 | 2011-09-01 | Ingo Schmidt-Wolf | Method for the generation of a cik cell and nk cell population |
CN102352342A (zh) * | 2011-09-30 | 2012-02-15 | 上海柯莱逊生物技术有限公司 | 一种用于扩增cik的方法及一种cik细胞制剂 |
CN102517213A (zh) * | 2011-12-29 | 2012-06-27 | 辽宁迈迪生物科技有限公司 | 用于t淋巴细胞的体外培养试剂盒 |
CN103013914A (zh) * | 2012-12-13 | 2013-04-03 | 吉林省拓华生物科技有限公司 | 体外培养杀伤性t细胞的方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2553133T3 (es) * | 2004-06-04 | 2015-12-04 | Cel-Sci Corporation | Método de modificación de la proporción de CD4/CD8 y del infiltrado celular mononuclear en un tumor |
US8211425B2 (en) * | 2005-12-21 | 2012-07-03 | Sentoclone International Ab | Method for treating disseminated cancer |
CN101418283A (zh) * | 2007-10-23 | 2009-04-29 | 范云峰 | 一种简单高效地制备cik细胞的方法 |
CN101386840A (zh) * | 2008-10-31 | 2009-03-18 | 江苏省人民医院 | Cd3-cd56+nk细胞高效扩增培养系统的构建方法 |
CN102174469B (zh) * | 2011-01-26 | 2012-11-21 | 宋鑫 | 一种有效培养肿瘤浸润淋巴细胞的方法 |
CN102827808B (zh) * | 2012-09-27 | 2014-06-18 | 高岱清 | 一种制备cik细胞的方法 |
-
2013
- 2013-08-02 CN CN201310334666.6A patent/CN103436492B/zh active Active
-
2014
- 2014-06-11 HK HK14105496.2A patent/HK1192282A1/zh unknown
- 2014-07-31 WO PCT/CN2014/083368 patent/WO2015014291A1/zh active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1990044A (zh) * | 2005-12-30 | 2007-07-04 | 上海中科英达生物技术有限公司 | 人体免疫活性细胞dccik抗肿瘤细胞制剂的制备方法及应用 |
CN101063108A (zh) * | 2007-04-25 | 2007-10-31 | 哈尔滨医科大学 | 一种高增殖力、高细胞毒活性cik细胞的制备方法 |
WO2011103882A1 (en) * | 2010-02-24 | 2011-09-01 | Ingo Schmidt-Wolf | Method for the generation of a cik cell and nk cell population |
CN102352342A (zh) * | 2011-09-30 | 2012-02-15 | 上海柯莱逊生物技术有限公司 | 一种用于扩增cik的方法及一种cik细胞制剂 |
CN102517213A (zh) * | 2011-12-29 | 2012-06-27 | 辽宁迈迪生物科技有限公司 | 用于t淋巴细胞的体外培养试剂盒 |
CN103013914A (zh) * | 2012-12-13 | 2013-04-03 | 吉林省拓华生物科技有限公司 | 体外培养杀伤性t细胞的方法 |
Non-Patent Citations (2)
Title |
---|
罗海华等: "人类CD8+记忆T细胞体外体外扩增方法的研究", 《中国病理生理杂志》, 15 July 2013 (2013-07-15) * |
许云云等: "IL-7对胸腺T细胞及树突状细胞体外分化发育的影响", 《中国免疫性杂志》, 31 December 2010 (2010-12-31), pages 108 - 112 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107208061A (zh) * | 2014-12-05 | 2017-09-26 | 伦敦国王学院 | γδ T细胞扩增方法 |
CN112662625A (zh) * | 2021-01-18 | 2021-04-16 | 杭州原生生物科技有限公司 | 一种t细胞培养基及其用于t细胞的扩增培养方法 |
CN116355846A (zh) * | 2021-12-28 | 2023-06-30 | 北京永泰生物制品有限公司 | 一种质量稳定可控的扩增活化淋巴细胞的方法及其用于防治神经科疾病中的用途 |
CN116355845A (zh) * | 2021-12-28 | 2023-06-30 | 北京永泰生物制品有限公司 | 一种质量稳定可控的扩增活化淋巴细胞的方法及其用于抗肿瘤用途 |
WO2023125704A1 (zh) * | 2021-12-28 | 2023-07-06 | 北京永泰生物制品有限公司 | 一种质量稳定可控的扩增活化淋巴细胞的方法及其用于防治神经科疾病中的用途 |
WO2023125696A3 (zh) * | 2021-12-28 | 2023-08-24 | 北京永泰生物制品有限公司 | 一种质量稳定可控的扩增活化淋巴细胞的方法及其用于抗肿瘤用途 |
CN116355845B (zh) * | 2021-12-28 | 2024-03-26 | 北京永泰生物制品有限公司 | 一种质量稳定可控的扩增活化淋巴细胞的方法及其用于抗肿瘤用途 |
CN114984048A (zh) * | 2022-06-16 | 2022-09-02 | 浙江百越生物技术有限公司 | 一种预防与治疗老年人行动迟缓的细胞疗法 |
CN117965445A (zh) * | 2024-04-02 | 2024-05-03 | 上海药明巨诺生物医药研发有限公司 | 一种用于细胞培养的组合物 |
Also Published As
Publication number | Publication date |
---|---|
HK1192282A1 (zh) | 2014-08-15 |
CN103436492B (zh) | 2016-03-02 |
WO2015014291A1 (zh) | 2015-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103436492B (zh) | 通过无血清培养扩增活化淋巴细胞的方法 | |
CN107326008B (zh) | 一种从外周血中高效高纯度扩增自然杀伤细胞的方法 | |
CN101302491B (zh) | 高效扩增活化淋巴细胞的方法和培养系统 | |
CN104357390B (zh) | 同时扩增cd3+cd56+cik细胞和cd3‑cd56+nk细胞的方法 | |
CN103849599B (zh) | 一种高效扩增自体nk细胞的培养基及培养方法 | |
CN102618498B (zh) | Hla-a0201限制性抗原特异性ctl制备方法 | |
CN102676454B (zh) | 一种脐带血来源的cik细胞的制备方法 | |
CN106434554A (zh) | Nk细胞的制备方法 | |
CN104938477A (zh) | 一种cik细胞冻存液及冻存方法 | |
CN106591231B (zh) | 促进cik细胞增殖分化的卡介菌多糖核酸、培养基、培养方法和应用 | |
CN106148282A (zh) | 一种自然杀伤细胞的培养方法 | |
CN103301449A (zh) | 一种大规模培养树突状细胞疫苗的制备方法及其应用 | |
CN104039333B (zh) | 移植物抗宿主疾病的治疗或预防方法 | |
CN106754704B (zh) | 免疫细胞体外诱导扩增的方法 | |
CN1990044A (zh) | 人体免疫活性细胞dccik抗肿瘤细胞制剂的制备方法及应用 | |
CN105296421B (zh) | 一种双特异性抗体活化的t细胞及制备方法与应用 | |
CN102719400B (zh) | Hla-a0201限制性抗cea抗原特异性ctl的制备方法 | |
CN105505871A (zh) | 一种有效扩增cik且提高其特异性杀瘤能力的方法 | |
CN103981144A (zh) | 自体血清抗原致敏dc-cik细胞的制备方法 | |
CN105969731B (zh) | 一种利用恶性胸腹水大量制备高杀伤活性til细胞的方法 | |
CN105106237A (zh) | 一种高效杀伤肿瘤细胞生物制剂 | |
CN104762261A (zh) | 一种肿瘤浸润淋巴细胞的分离方法 | |
CN109957543A (zh) | 利用脐带血大量扩增脐血nk细胞的方法 | |
CN108148805B (zh) | 一种人Tscm细胞及其制备方法和应用 | |
CN106479973B (zh) | 一种体外iak免疫细胞培养方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1192282 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1192282 Country of ref document: HK |
|
TR01 | Transfer of patent right |
Effective date of registration: 20190725 Address after: 100176 No. 1, Kangding Street, Daxing Economic and Technological Development Zone, Beijing, 4 buildings and 2 floors Patentee after: BEIJING YONGTAI IMMUNITY APPLICATION TECHNOLOGY CO., LTD. Address before: 100071 Beijing Fengtai District Fengtai Road 139 Xifulou 226 Patentee before: ImmunoTech Beijing Limited |
|
TR01 | Transfer of patent right |